Global pharma shares sink as Biden backs COVID-19 vaccine IP waiver

reuters2021-05-06

Shares of COVID-19 vaccine makers plungedafter U.S. President Joe Bidenbacked a proposed waiver for intellectual property rightseven as the pharmaceutical industry, analysts and experts doubted its ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

Wallstrtbets
2021-05-09
Wallstrtbets
Noted.
sUs
2021-05-08
sUs
Good?
Kel9670ong
2021-05-07
Kel9670ong
Better not to have too many brand of vaccine
Bibop
2021-05-07
Bibop
Greedy pharma company got slash.
mcwood
2021-05-07
mcwood
[得意]
小股神来也
2021-05-07
小股神来也
Wow
- 茁壮成长的韭菜儿:
  ok
- 小股神来也:
  oo
- 茁壮成长的韭菜儿:
  ooo

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1139680950?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-05-06 22:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1139680950","market":"us","top_or_hot":-1,"title":"Global pharma shares sink as Biden backs COVID-19 vaccine IP waiver","media":"reuters","content":"<div>\nShares of COVID-19 vaccine makers plungedafter U.S. President Joe Bidenbacked a proposed waiver for intellectual property rightseven as the pharmaceutical industry, analysts and experts doubted its ...\n\n<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/pharma-shares-reel-after-biden-backs-covid-19-vaccine-ip-waiver-2021-05-06/\">网页链接</a>\n\n</div>\n","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Global pharma shares sink as Biden backs COVID-19 vaccine IP waiver</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGlobal pharma shares sink as Biden backs COVID-19 vaccine IP waiver\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-06 22:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/business/healthcare-pharmaceuticals/pharma-shares-reel-after-biden-backs-covid-19-vaccine-ip-waiver-2021-05-06/>reuters</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nShares of COVID-19 vaccine makers plungedafter U.S. President Joe Bidenbacked a proposed waiver for intellectual property rightseven as the pharmaceutical industry, analysts and experts doubted its ...\n\n<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/pharma-shares-reel-after-biden-backs-covid-19-vaccine-ip-waiver-2021-05-06/\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/pharma-shares-reel-after-biden-backs-covid-19-vaccine-ip-waiver-2021-05-06/","article_id":"1139680950","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1139680950","pubTimestamp":1620311931,"columns":[],"sourceInfo":null,"weMediaInfo":null,"summary":"Shares of COVID-19 vaccine makers plungedafter U.S. President Joe Bidenbacked a proposed waiver for ","collect":0,"end_time":0,"defaultTopTitle":"reuters.com","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"拜登支持新冠疫苗知识产权豁免全球医药股下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{},"content_text":"Shares of COVID-19 vaccine makers plungedafter U.S. President Joe Bidenbacked a proposed waiver for intellectual property rightseven as the pharmaceutical industry, analysts and experts doubted its impact, saying the real problem is a lack of raw materials and know-how.Pfizer, Moderna, Novavax(NVAX.O)and U.S. shares of BioNTech were down between 4% and 10% on Thursday. The slide in stocks was understandable, but likely an over-reaction, Zhiqiang Shu, senior biotechnology analyst at Berenberg in New York, said.\"The production of mRNA vaccines is not just about intellectual property. A lot of other things are in play, such as manufacturing know-how and capacity. Other companies or countries are unlikely to produce mRNA shots quickly,\" he said.The Biden administration move drew applause from patent activists and the World Health Organization as it could increase availability of vaccines to poorer nations including India, which is under the grip of a deadly second wave of infection.However, implementing such a move could be a lengthy process as all 164 WTO member countries are required to arrive at a consent.The pharmaceutical industry, which has long defended patents as the key to research and development of new treatments, criticized the move, with its biggest lobby group warning that it would undermine pandemic response and compromise safety.Several pharmaceutical analysts said IP waivers may on the surface help a world facing a pandemic, but manufacturing the vaccines was a barrier.Jefferies analyst Michael Yee said while the proposal was not a good \"headline\" for biotech and could affect earnings, in reality, the bottleneck is neither access nor patents (or price) but simply that there aren't enough vials, raw materials.It would probably take a year after an IP deal was struck for anyone to make a vaccine, Scott Gottlieb, former head of the U.S. Food and Drug Administration and Pfizer board member said in a CNBC interview.Moderna CEO Stephan Bancel too doubted if the IP waiver would help as its technology has been open since October to anyone for use during the pandemic.\"You cannot go hire people who know how to make the mRNA. Those people don't exist,\" he told investors.Pharma shares lost ground elsewhere too, with Germany's Curevac(5CV.DE), which has sought approval for its COVID-19 vaccine, tumbling as much as 15%.Chinese vaccine makersslumpedwith CanSino Biologics Inc , a single-dose COVID-19 vaccine maker, down 16%. Its Hong Kong shares(6185.HK)dived as much as 22%. Shares in London-listed AstraZeneca(AZN.L)were largely unchanged.","kind":"news","is_publish_news":false,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[{"id":107506306,"gmtCreate":1620519464505,"gmtModify":1634198344944,"author":{"id":"3566244878628904","authorId":"3566244878628904","name":"Wallstrtbets","avatar":"https://static.tigerbbs.com/6c38bbee1121ea92508ad9508fa15c5e","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3566244878628904","authorIdStr":"3566244878628904"},"htmlText":"Noted.","listText":"Noted.","text":"Noted.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/107506306","repostId":1139680950,"repostType":4,"repost":{"id":"1139680950","kind":"news","pubTimestamp":1620311931,"share":"https://www.laohu8.com/m/news/1139680950?lang=zh_CN&edition=full","pubTime":"2021-05-06 22:38","market":"us","language":"en","title":"Global pharma shares sink as Biden backs COVID-19 vaccine IP waiver<blockquote>拜登支持COVID-19疫苗知识产权豁免，全球制药股下跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1139680950","media":"reuters","summary":"Shares of COVID-19 vaccine makers plungedafter U.S. President Joe Bidenbacked a proposed waiver for ","content":"Shares of COVID-19 vaccine makers plungedafter U.S. President Joe Bidenbacked a proposed waiver for intellectual property rightseven as the pharmaceutical industry, analysts and experts doubted its impact, saying the real problem is a lack of raw materials and know-how.<blockquote>在美国总统乔·拜登支持拟议的知识产权豁免后，COVID-19疫苗制造商的股价暴跌尽管制药行业，分析师和专家仍怀疑其影响，称真正的问题是缺乏原材料和专业知识。</blockquote>Pfizer, Moderna, Novavax(NVAX.O)and U.S. shares of BioNTech were down between 4% and 10% on Thursday. The slide in stocks was understandable, but likely an over-reaction, Zhiqiang Shu, senior biotechnology analyst at Berenberg in New York, said.<blockquote>辉瑞、Moderna、Novavax(NVAX.O)和BioNTech的美股周四下跌4%至10%。纽约贝伦贝格高级生物技术分析师舒志强表示，股市下跌是可以理解的，但可能是反应过度。</blockquote>\"The production of mRNA vaccines is not just about intellectual property. A lot of other things are in play, such as manufacturing know-how and capacity. Other companies or countries are unlikely to produce mRNA shots quickly,\" he said.<blockquote>“mRNA疫苗的生产不仅仅与知识产权有关。还有很多其他因素在起作用，例如制造技术和产能。其他公司或国家不太可能快速生产mRNA疫苗，”他说。</blockquote>The Biden administration move drew applause from patent activists and the World Health Organization as it could increase availability of vaccines to poorer nations including India, which is under the grip of a deadly second wave of infection.<blockquote>拜登政府的举动赢得了专利活动人士和世界卫生组织的掌声，因为它可能会增加包括印度在内的较贫穷国家的疫苗供应，印度正受到致命的第二波感染。</blockquote>However, implementing such a move could be a lengthy process as all 164 WTO member countries are required to arrive at a consent.<blockquote>然而，实施这一举措可能是一个漫长的过程，因为所有164个世贸组织成员国都需要达成一致。</blockquote>The pharmaceutical industry, which has long defended patents as the key to research and development of new treatments, criticized the move, with its biggest lobby group warning that it would undermine pandemic response and compromise safety.<blockquote>长期以来一直捍卫专利是新疗法研发关键的制药业批评了此举，其最大的游说团体警告称，这将破坏大流行应对措施并损害安全。</blockquote>Several pharmaceutical analysts said IP waivers may on the surface help a world facing a pandemic, but manufacturing the vaccines was a barrier.<blockquote>几位制药分析师表示，知识产权豁免表面上可能有助于面临大流行的世界，但生产疫苗是一个障碍。</blockquote>Jefferies analyst Michael Yee said while the proposal was not a good \"headline\" for biotech and could affect earnings, in reality, the bottleneck is neither access nor patents (or price) but simply that there aren't enough vials, raw materials.<blockquote>杰富瑞(Jefferies)分析师Michael Yee表示，虽然该提案对生物技术来说不是一个好的“头条新闻”，并且可能会影响盈利，但实际上，瓶颈既不是获取也不是专利（或价格），而只是没有足够的小瓶和原材料。</blockquote>It would probably take a year after an IP deal was struck for anyone to make a vaccine, Scott Gottlieb, former head of the U.S. Food and Drug Administration and Pfizer board member said in a CNBC interview.<blockquote>美国前总统斯科特·戈特利布(Scott Gottlieb)表示，在达成知识产权协议后，任何人都可能需要一年时间才能制造疫苗。美国食品药品监督管理局和辉瑞董事会成员在接受CNBC采访时表示。</blockquote>Moderna CEO Stephan Bancel too doubted if the IP waiver would help as its technology has been open since October to anyone for use during the pandemic.<blockquote>Moderna首席执行官Stephan Bancel也怀疑知识产权豁免是否会有所帮助，因为其技术自10月份以来一直向任何人开放，可在大流行期间使用。</blockquote>\"You cannot go hire people who know how to make the mRNA. Those people don't exist,\" he told investors.<blockquote>“你不能雇佣知道如何制造mRNA的人。这些人并不存在，”他告诉投资者。</blockquote>Pharma shares lost ground elsewhere too, with Germany's Curevac(5CV.DE), which has sought approval for its COVID-19 vaccine, tumbling as much as 15%.<blockquote>其他地方的制药股也下跌，德国Curevac(5CV.DE)股价下跌15%，该公司已寻求其COVID-19疫苗的批准。</blockquote>Chinese vaccine makersslumpedwith CanSino Biologics Inc , a single-dose COVID-19 vaccine maker, down 16%. Its Hong Kong shares(6185.HK)dived as much as 22%. Shares in London-listed AstraZeneca(AZN.L)were largely unchanged.<blockquote>中国疫苗制造商股价暴跌，单剂COVID-19疫苗制造商康希诺生物公司股价下跌16%。其港股（6185.HK）跌幅高达22%。在伦敦上市的阿斯利康(AZN.L)的股价基本没有变化。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Global pharma shares sink as Biden backs COVID-19 vaccine IP waiver<blockquote>拜登支持COVID-19疫苗知识产权豁免，全球制药股下跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGlobal pharma shares sink as Biden backs COVID-19 vaccine IP waiver<blockquote>拜登支持COVID-19疫苗知识产权豁免，全球制药股下跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nreuters2021-05-06 22:38\n\n</h4>\n</header>\n<article>\nShares of COVID-19 vaccine makers plungedafter U.S. President Joe Bidenbacked a proposed waiver for intellectual property rightseven as the pharmaceutical industry, analysts and experts doubted its impact, saying the real problem is a lack of raw materials and know-how.<blockquote>在美国总统乔·拜登支持拟议的知识产权豁免后，COVID-19疫苗制造商的股价暴跌尽管制药行业，分析师和专家仍怀疑其影响，称真正的问题是缺乏原材料和专业知识。</blockquote>Pfizer, Moderna, Novavax(NVAX.O)and U.S. shares of BioNTech were down between 4% and 10% on Thursday. The slide in stocks was understandable, but likely an over-reaction, Zhiqiang Shu, senior biotechnology analyst at Berenberg in New York, said.<blockquote>辉瑞、Moderna、Novavax(NVAX.O)和BioNTech的美股周四下跌4%至10%。纽约贝伦贝格高级生物技术分析师舒志强表示，股市下跌是可以理解的，但可能是反应过度。</blockquote>\"The production of mRNA vaccines is not just about intellectual property. A lot of other things are in play, such as manufacturing know-how and capacity. Other companies or countries are unlikely to produce mRNA shots quickly,\" he said.<blockquote>“mRNA疫苗的生产不仅仅与知识产权有关。还有很多其他因素在起作用，例如制造技术和产能。其他公司或国家不太可能快速生产mRNA疫苗，”他说。</blockquote>The Biden administration move drew applause from patent activists and the World Health Organization as it could increase availability of vaccines to poorer nations including India, which is under the grip of a deadly second wave of infection.<blockquote>拜登政府的举动赢得了专利活动人士和世界卫生组织的掌声，因为它可能会增加包括印度在内的较贫穷国家的疫苗供应，印度正受到致命的第二波感染。</blockquote>However, implementing such a move could be a lengthy process as all 164 WTO member countries are required to arrive at a consent.<blockquote>然而，实施这一举措可能是一个漫长的过程，因为所有164个世贸组织成员国都需要达成一致。</blockquote>The pharmaceutical industry, which has long defended patents as the key to research and development of new treatments, criticized the move, with its biggest lobby group warning that it would undermine pandemic response and compromise safety.<blockquote>长期以来一直捍卫专利是新疗法研发关键的制药业批评了此举，其最大的游说团体警告称，这将破坏大流行应对措施并损害安全。</blockquote>Several pharmaceutical analysts said IP waivers may on the surface help a world facing a pandemic, but manufacturing the vaccines was a barrier.<blockquote>几位制药分析师表示，知识产权豁免表面上可能有助于面临大流行的世界，但生产疫苗是一个障碍。</blockquote>Jefferies analyst Michael Yee said while the proposal was not a good \"headline\" for biotech and could affect earnings, in reality, the bottleneck is neither access nor patents (or price) but simply that there aren't enough vials, raw materials.<blockquote>杰富瑞(Jefferies)分析师Michael Yee表示，虽然该提案对生物技术来说不是一个好的“头条新闻”，并且可能会影响盈利，但实际上，瓶颈既不是获取也不是专利（或价格），而只是没有足够的小瓶和原材料。</blockquote>It would probably take a year after an IP deal was struck for anyone to make a vaccine, Scott Gottlieb, former head of the U.S. Food and Drug Administration and Pfizer board member said in a CNBC interview.<blockquote>美国前总统斯科特·戈特利布(Scott Gottlieb)表示，在达成知识产权协议后，任何人都可能需要一年时间才能制造疫苗。美国食品药品监督管理局和辉瑞董事会成员在接受CNBC采访时表示。</blockquote>Moderna CEO Stephan Bancel too doubted if the IP waiver would help as its technology has been open since October to anyone for use during the pandemic.<blockquote>Moderna首席执行官Stephan Bancel也怀疑知识产权豁免是否会有所帮助，因为其技术自10月份以来一直向任何人开放，可在大流行期间使用。</blockquote>\"You cannot go hire people who know how to make the mRNA. Those people don't exist,\" he told investors.<blockquote>“你不能雇佣知道如何制造mRNA的人。这些人并不存在，”他告诉投资者。</blockquote>Pharma shares lost ground elsewhere too, with Germany's Curevac(5CV.DE), which has sought approval for its COVID-19 vaccine, tumbling as much as 15%.<blockquote>其他地方的制药股也下跌，德国Curevac(5CV.DE)股价下跌15%，该公司已寻求其COVID-19疫苗的批准。</blockquote>Chinese vaccine makersslumpedwith CanSino Biologics Inc , a single-dose COVID-19 vaccine maker, down 16%. Its Hong Kong shares(6185.HK)dived as much as 22%. Shares in London-listed AstraZeneca(AZN.L)were largely unchanged.<blockquote>中国疫苗制造商股价暴跌，单剂COVID-19疫苗制造商康希诺生物公司股价下跌16%。其港股（6185.HK）跌幅高达22%。在伦敦上市的阿斯利康(AZN.L)的股价基本没有变化。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/pharma-shares-reel-after-biden-backs-covid-19-vaccine-ip-waiver-2021-05-06/\">reuters</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/pharma-shares-reel-after-biden-backs-covid-19-vaccine-ip-waiver-2021-05-06/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1139680950","content_text":"Shares of COVID-19 vaccine makers plungedafter U.S. President Joe Bidenbacked a proposed waiver for intellectual property rightseven as the pharmaceutical industry, analysts and experts doubted its impact, saying the real problem is a lack of raw materials and know-how.Pfizer, Moderna, Novavax(NVAX.O)and U.S. shares of BioNTech were down between 4% and 10% on Thursday. The slide in stocks was understandable, but likely an over-reaction, Zhiqiang Shu, senior biotechnology analyst at Berenberg in New York, said.\"The production of mRNA vaccines is not just about intellectual property. A lot of other things are in play, such as manufacturing know-how and capacity. Other companies or countries are unlikely to produce mRNA shots quickly,\" he said.The Biden administration move drew applause from patent activists and the World Health Organization as it could increase availability of vaccines to poorer nations including India, which is under the grip of a deadly second wave of infection.However, implementing such a move could be a lengthy process as all 164 WTO member countries are required to arrive at a consent.The pharmaceutical industry, which has long defended patents as the key to research and development of new treatments, criticized the move, with its biggest lobby group warning that it would undermine pandemic response and compromise safety.Several pharmaceutical analysts said IP waivers may on the surface help a world facing a pandemic, but manufacturing the vaccines was a barrier.Jefferies analyst Michael Yee said while the proposal was not a good \"headline\" for biotech and could affect earnings, in reality, the bottleneck is neither access nor patents (or price) but simply that there aren't enough vials, raw materials.It would probably take a year after an IP deal was struck for anyone to make a vaccine, Scott Gottlieb, former head of the U.S. Food and Drug Administration and Pfizer board member said in a CNBC interview.Moderna CEO Stephan Bancel too doubted if the IP waiver would help as its technology has been open since October to anyone for use during the pandemic.\"You cannot go hire people who know how to make the mRNA. Those people don't exist,\" he told investors.Pharma shares lost ground elsewhere too, with Germany's Curevac(5CV.DE), which has sought approval for its COVID-19 vaccine, tumbling as much as 15%.Chinese vaccine makersslumpedwith CanSino Biologics Inc , a single-dose COVID-19 vaccine maker, down 16%. Its Hong Kong shares(6185.HK)dived as much as 22%. Shares in London-listed AstraZeneca(AZN.L)were largely unchanged.","news_type":1,"symbols_score_info":{}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":107819630,"gmtCreate":1620462829520,"gmtModify":1634198561366,"author":{"id":"3574914161995189","authorId":"3574914161995189","name":"sUs","avatar":"https://static.tigerbbs.com/20333dcc0f0c43df9ba7c18ce429ae93","vip":1,"crmLevel":11,"crmLevelSwitch":0,"idStr":"3574914161995189","authorIdStr":"3574914161995189"},"htmlText":"Good?&nbsp;","listText":"Good?&nbsp;","text":"Good?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/107819630","repostId":1139680950,"repostType":4,"repost":{"id":"1139680950","kind":"news","pubTimestamp":1620311931,"share":"https://www.laohu8.com/m/news/1139680950?lang=zh_CN&edition=full","pubTime":"2021-05-06 22:38","market":"us","language":"en","title":"Global pharma shares sink as Biden backs COVID-19 vaccine IP waiver<blockquote>拜登支持COVID-19疫苗知识产权豁免，全球制药股下跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1139680950","media":"reuters","summary":"Shares of COVID-19 vaccine makers plungedafter U.S. President Joe Bidenbacked a proposed waiver for ","content":"Shares of COVID-19 vaccine makers plungedafter U.S. President Joe Bidenbacked a proposed waiver for intellectual property rightseven as the pharmaceutical industry, analysts and experts doubted its impact, saying the real problem is a lack of raw materials and know-how.<blockquote>在美国总统乔·拜登支持拟议的知识产权豁免后，COVID-19疫苗制造商的股价暴跌尽管制药行业，分析师和专家仍怀疑其影响，称真正的问题是缺乏原材料和专业知识。</blockquote>Pfizer, Moderna, Novavax(NVAX.O)and U.S. shares of BioNTech were down between 4% and 10% on Thursday. The slide in stocks was understandable, but likely an over-reaction, Zhiqiang Shu, senior biotechnology analyst at Berenberg in New York, said.<blockquote>辉瑞、Moderna、Novavax(NVAX.O)和BioNTech的美股周四下跌4%至10%。纽约贝伦贝格高级生物技术分析师舒志强表示，股市下跌是可以理解的，但可能是反应过度。</blockquote>\"The production of mRNA vaccines is not just about intellectual property. A lot of other things are in play, such as manufacturing know-how and capacity. Other companies or countries are unlikely to produce mRNA shots quickly,\" he said.<blockquote>“mRNA疫苗的生产不仅仅与知识产权有关。还有很多其他因素在起作用，例如制造技术和产能。其他公司或国家不太可能快速生产mRNA疫苗，”他说。</blockquote>The Biden administration move drew applause from patent activists and the World Health Organization as it could increase availability of vaccines to poorer nations including India, which is under the grip of a deadly second wave of infection.<blockquote>拜登政府的举动赢得了专利活动人士和世界卫生组织的掌声，因为它可能会增加包括印度在内的较贫穷国家的疫苗供应，印度正受到致命的第二波感染。</blockquote>However, implementing such a move could be a lengthy process as all 164 WTO member countries are required to arrive at a consent.<blockquote>然而，实施这一举措可能是一个漫长的过程，因为所有164个世贸组织成员国都需要达成一致。</blockquote>The pharmaceutical industry, which has long defended patents as the key to research and development of new treatments, criticized the move, with its biggest lobby group warning that it would undermine pandemic response and compromise safety.<blockquote>长期以来一直捍卫专利是新疗法研发关键的制药业批评了此举，其最大的游说团体警告称，这将破坏大流行应对措施并损害安全。</blockquote>Several pharmaceutical analysts said IP waivers may on the surface help a world facing a pandemic, but manufacturing the vaccines was a barrier.<blockquote>几位制药分析师表示，知识产权豁免表面上可能有助于面临大流行的世界，但生产疫苗是一个障碍。</blockquote>Jefferies analyst Michael Yee said while the proposal was not a good \"headline\" for biotech and could affect earnings, in reality, the bottleneck is neither access nor patents (or price) but simply that there aren't enough vials, raw materials.<blockquote>杰富瑞(Jefferies)分析师Michael Yee表示，虽然该提案对生物技术来说不是一个好的“头条新闻”，并且可能会影响盈利，但实际上，瓶颈既不是获取也不是专利（或价格），而只是没有足够的小瓶和原材料。</blockquote>It would probably take a year after an IP deal was struck for anyone to make a vaccine, Scott Gottlieb, former head of the U.S. Food and Drug Administration and Pfizer board member said in a CNBC interview.<blockquote>美国前总统斯科特·戈特利布(Scott Gottlieb)表示，在达成知识产权协议后，任何人都可能需要一年时间才能制造疫苗。美国食品药品监督管理局和辉瑞董事会成员在接受CNBC采访时表示。</blockquote>Moderna CEO Stephan Bancel too doubted if the IP waiver would help as its technology has been open since October to anyone for use during the pandemic.<blockquote>Moderna首席执行官Stephan Bancel也怀疑知识产权豁免是否会有所帮助，因为其技术自10月份以来一直向任何人开放，可在大流行期间使用。</blockquote>\"You cannot go hire people who know how to make the mRNA. Those people don't exist,\" he told investors.<blockquote>“你不能雇佣知道如何制造mRNA的人。这些人并不存在，”他告诉投资者。</blockquote>Pharma shares lost ground elsewhere too, with Germany's Curevac(5CV.DE), which has sought approval for its COVID-19 vaccine, tumbling as much as 15%.<blockquote>其他地方的制药股也下跌，德国Curevac(5CV.DE)股价下跌15%，该公司已寻求其COVID-19疫苗的批准。</blockquote>Chinese vaccine makersslumpedwith CanSino Biologics Inc , a single-dose COVID-19 vaccine maker, down 16%. Its Hong Kong shares(6185.HK)dived as much as 22%. Shares in London-listed AstraZeneca(AZN.L)were largely unchanged.<blockquote>中国疫苗制造商股价暴跌，单剂COVID-19疫苗制造商康希诺生物公司股价下跌16%。其港股（6185.HK）跌幅高达22%。在伦敦上市的阿斯利康(AZN.L)的股价基本没有变化。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Global pharma shares sink as Biden backs COVID-19 vaccine IP waiver<blockquote>拜登支持COVID-19疫苗知识产权豁免，全球制药股下跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGlobal pharma shares sink as Biden backs COVID-19 vaccine IP waiver<blockquote>拜登支持COVID-19疫苗知识产权豁免，全球制药股下跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nreuters2021-05-06 22:38\n\n</h4>\n</header>\n<article>\nShares of COVID-19 vaccine makers plungedafter U.S. President Joe Bidenbacked a proposed waiver for intellectual property rightseven as the pharmaceutical industry, analysts and experts doubted its impact, saying the real problem is a lack of raw materials and know-how.<blockquote>在美国总统乔·拜登支持拟议的知识产权豁免后，COVID-19疫苗制造商的股价暴跌尽管制药行业，分析师和专家仍怀疑其影响，称真正的问题是缺乏原材料和专业知识。</blockquote>Pfizer, Moderna, Novavax(NVAX.O)and U.S. shares of BioNTech were down between 4% and 10% on Thursday. The slide in stocks was understandable, but likely an over-reaction, Zhiqiang Shu, senior biotechnology analyst at Berenberg in New York, said.<blockquote>辉瑞、Moderna、Novavax(NVAX.O)和BioNTech的美股周四下跌4%至10%。纽约贝伦贝格高级生物技术分析师舒志强表示，股市下跌是可以理解的，但可能是反应过度。</blockquote>\"The production of mRNA vaccines is not just about intellectual property. A lot of other things are in play, such as manufacturing know-how and capacity. Other companies or countries are unlikely to produce mRNA shots quickly,\" he said.<blockquote>“mRNA疫苗的生产不仅仅与知识产权有关。还有很多其他因素在起作用，例如制造技术和产能。其他公司或国家不太可能快速生产mRNA疫苗，”他说。</blockquote>The Biden administration move drew applause from patent activists and the World Health Organization as it could increase availability of vaccines to poorer nations including India, which is under the grip of a deadly second wave of infection.<blockquote>拜登政府的举动赢得了专利活动人士和世界卫生组织的掌声，因为它可能会增加包括印度在内的较贫穷国家的疫苗供应，印度正受到致命的第二波感染。</blockquote>However, implementing such a move could be a lengthy process as all 164 WTO member countries are required to arrive at a consent.<blockquote>然而，实施这一举措可能是一个漫长的过程，因为所有164个世贸组织成员国都需要达成一致。</blockquote>The pharmaceutical industry, which has long defended patents as the key to research and development of new treatments, criticized the move, with its biggest lobby group warning that it would undermine pandemic response and compromise safety.<blockquote>长期以来一直捍卫专利是新疗法研发关键的制药业批评了此举，其最大的游说团体警告称，这将破坏大流行应对措施并损害安全。</blockquote>Several pharmaceutical analysts said IP waivers may on the surface help a world facing a pandemic, but manufacturing the vaccines was a barrier.<blockquote>几位制药分析师表示，知识产权豁免表面上可能有助于面临大流行的世界，但生产疫苗是一个障碍。</blockquote>Jefferies analyst Michael Yee said while the proposal was not a good \"headline\" for biotech and could affect earnings, in reality, the bottleneck is neither access nor patents (or price) but simply that there aren't enough vials, raw materials.<blockquote>杰富瑞(Jefferies)分析师Michael Yee表示，虽然该提案对生物技术来说不是一个好的“头条新闻”，并且可能会影响盈利，但实际上，瓶颈既不是获取也不是专利（或价格），而只是没有足够的小瓶和原材料。</blockquote>It would probably take a year after an IP deal was struck for anyone to make a vaccine, Scott Gottlieb, former head of the U.S. Food and Drug Administration and Pfizer board member said in a CNBC interview.<blockquote>美国前总统斯科特·戈特利布(Scott Gottlieb)表示，在达成知识产权协议后，任何人都可能需要一年时间才能制造疫苗。美国食品药品监督管理局和辉瑞董事会成员在接受CNBC采访时表示。</blockquote>Moderna CEO Stephan Bancel too doubted if the IP waiver would help as its technology has been open since October to anyone for use during the pandemic.<blockquote>Moderna首席执行官Stephan Bancel也怀疑知识产权豁免是否会有所帮助，因为其技术自10月份以来一直向任何人开放，可在大流行期间使用。</blockquote>\"You cannot go hire people who know how to make the mRNA. Those people don't exist,\" he told investors.<blockquote>“你不能雇佣知道如何制造mRNA的人。这些人并不存在，”他告诉投资者。</blockquote>Pharma shares lost ground elsewhere too, with Germany's Curevac(5CV.DE), which has sought approval for its COVID-19 vaccine, tumbling as much as 15%.<blockquote>其他地方的制药股也下跌，德国Curevac(5CV.DE)股价下跌15%，该公司已寻求其COVID-19疫苗的批准。</blockquote>Chinese vaccine makersslumpedwith CanSino Biologics Inc , a single-dose COVID-19 vaccine maker, down 16%. Its Hong Kong shares(6185.HK)dived as much as 22%. Shares in London-listed AstraZeneca(AZN.L)were largely unchanged.<blockquote>中国疫苗制造商股价暴跌，单剂COVID-19疫苗制造商康希诺生物公司股价下跌16%。其港股（6185.HK）跌幅高达22%。在伦敦上市的阿斯利康(AZN.L)的股价基本没有变化。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/pharma-shares-reel-after-biden-backs-covid-19-vaccine-ip-waiver-2021-05-06/\">reuters</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/pharma-shares-reel-after-biden-backs-covid-19-vaccine-ip-waiver-2021-05-06/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1139680950","content_text":"Shares of COVID-19 vaccine makers plungedafter U.S. President Joe Bidenbacked a proposed waiver for intellectual property rightseven as the pharmaceutical industry, analysts and experts doubted its impact, saying the real problem is a lack of raw materials and know-how.Pfizer, Moderna, Novavax(NVAX.O)and U.S. shares of BioNTech were down between 4% and 10% on Thursday. The slide in stocks was understandable, but likely an over-reaction, Zhiqiang Shu, senior biotechnology analyst at Berenberg in New York, said.\"The production of mRNA vaccines is not just about intellectual property. A lot of other things are in play, such as manufacturing know-how and capacity. Other companies or countries are unlikely to produce mRNA shots quickly,\" he said.The Biden administration move drew applause from patent activists and the World Health Organization as it could increase availability of vaccines to poorer nations including India, which is under the grip of a deadly second wave of infection.However, implementing such a move could be a lengthy process as all 164 WTO member countries are required to arrive at a consent.The pharmaceutical industry, which has long defended patents as the key to research and development of new treatments, criticized the move, with its biggest lobby group warning that it would undermine pandemic response and compromise safety.Several pharmaceutical analysts said IP waivers may on the surface help a world facing a pandemic, but manufacturing the vaccines was a barrier.Jefferies analyst Michael Yee said while the proposal was not a good \"headline\" for biotech and could affect earnings, in reality, the bottleneck is neither access nor patents (or price) but simply that there aren't enough vials, raw materials.It would probably take a year after an IP deal was struck for anyone to make a vaccine, Scott Gottlieb, former head of the U.S. Food and Drug Administration and Pfizer board member said in a CNBC interview.Moderna CEO Stephan Bancel too doubted if the IP waiver would help as its technology has been open since October to anyone for use during the pandemic.\"You cannot go hire people who know how to make the mRNA. Those people don't exist,\" he told investors.Pharma shares lost ground elsewhere too, with Germany's Curevac(5CV.DE), which has sought approval for its COVID-19 vaccine, tumbling as much as 15%.Chinese vaccine makersslumpedwith CanSino Biologics Inc , a single-dose COVID-19 vaccine maker, down 16%. Its Hong Kong shares(6185.HK)dived as much as 22%. Shares in London-listed AstraZeneca(AZN.L)were largely unchanged.","news_type":1,"symbols_score_info":{}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":104852399,"gmtCreate":1620377466111,"gmtModify":1634205663517,"author":{"id":"3578468158955348","authorId":"3578468158955348","name":"Kel9670ong","avatar":"https://static.tigerbbs.com/bd86c42e207fbd94e7f8877a29457d71","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3578468158955348","authorIdStr":"3578468158955348"},"htmlText":"Better not to have too many brand of vaccine","listText":"Better not to have too many brand of vaccine","text":"Better not to have too many brand of vaccine","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/104852399","repostId":1139680950,"repostType":4,"repost":{"id":"1139680950","kind":"news","pubTimestamp":1620311931,"share":"https://www.laohu8.com/m/news/1139680950?lang=zh_CN&edition=full","pubTime":"2021-05-06 22:38","market":"us","language":"en","title":"Global pharma shares sink as Biden backs COVID-19 vaccine IP waiver<blockquote>拜登支持COVID-19疫苗知识产权豁免，全球制药股下跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1139680950","media":"reuters","summary":"Shares of COVID-19 vaccine makers plungedafter U.S. President Joe Bidenbacked a proposed waiver for ","content":"Shares of COVID-19 vaccine makers plungedafter U.S. President Joe Bidenbacked a proposed waiver for intellectual property rightseven as the pharmaceutical industry, analysts and experts doubted its impact, saying the real problem is a lack of raw materials and know-how.<blockquote>在美国总统乔·拜登支持拟议的知识产权豁免后，COVID-19疫苗制造商的股价暴跌尽管制药行业，分析师和专家仍怀疑其影响，称真正的问题是缺乏原材料和专业知识。</blockquote>Pfizer, Moderna, Novavax(NVAX.O)and U.S. shares of BioNTech were down between 4% and 10% on Thursday. The slide in stocks was understandable, but likely an over-reaction, Zhiqiang Shu, senior biotechnology analyst at Berenberg in New York, said.<blockquote>辉瑞、Moderna、Novavax(NVAX.O)和BioNTech的美股周四下跌4%至10%。纽约贝伦贝格高级生物技术分析师舒志强表示，股市下跌是可以理解的，但可能是反应过度。</blockquote>\"The production of mRNA vaccines is not just about intellectual property. A lot of other things are in play, such as manufacturing know-how and capacity. Other companies or countries are unlikely to produce mRNA shots quickly,\" he said.<blockquote>“mRNA疫苗的生产不仅仅与知识产权有关。还有很多其他因素在起作用，例如制造技术和产能。其他公司或国家不太可能快速生产mRNA疫苗，”他说。</blockquote>The Biden administration move drew applause from patent activists and the World Health Organization as it could increase availability of vaccines to poorer nations including India, which is under the grip of a deadly second wave of infection.<blockquote>拜登政府的举动赢得了专利活动人士和世界卫生组织的掌声，因为它可能会增加包括印度在内的较贫穷国家的疫苗供应，印度正受到致命的第二波感染。</blockquote>However, implementing such a move could be a lengthy process as all 164 WTO member countries are required to arrive at a consent.<blockquote>然而，实施这一举措可能是一个漫长的过程，因为所有164个世贸组织成员国都需要达成一致。</blockquote>The pharmaceutical industry, which has long defended patents as the key to research and development of new treatments, criticized the move, with its biggest lobby group warning that it would undermine pandemic response and compromise safety.<blockquote>长期以来一直捍卫专利是新疗法研发关键的制药业批评了此举，其最大的游说团体警告称，这将破坏大流行应对措施并损害安全。</blockquote>Several pharmaceutical analysts said IP waivers may on the surface help a world facing a pandemic, but manufacturing the vaccines was a barrier.<blockquote>几位制药分析师表示，知识产权豁免表面上可能有助于面临大流行的世界，但生产疫苗是一个障碍。</blockquote>Jefferies analyst Michael Yee said while the proposal was not a good \"headline\" for biotech and could affect earnings, in reality, the bottleneck is neither access nor patents (or price) but simply that there aren't enough vials, raw materials.<blockquote>杰富瑞(Jefferies)分析师Michael Yee表示，虽然该提案对生物技术来说不是一个好的“头条新闻”，并且可能会影响盈利，但实际上，瓶颈既不是获取也不是专利（或价格），而只是没有足够的小瓶和原材料。</blockquote>It would probably take a year after an IP deal was struck for anyone to make a vaccine, Scott Gottlieb, former head of the U.S. Food and Drug Administration and Pfizer board member said in a CNBC interview.<blockquote>美国前总统斯科特·戈特利布(Scott Gottlieb)表示，在达成知识产权协议后，任何人都可能需要一年时间才能制造疫苗。美国食品药品监督管理局和辉瑞董事会成员在接受CNBC采访时表示。</blockquote>Moderna CEO Stephan Bancel too doubted if the IP waiver would help as its technology has been open since October to anyone for use during the pandemic.<blockquote>Moderna首席执行官Stephan Bancel也怀疑知识产权豁免是否会有所帮助，因为其技术自10月份以来一直向任何人开放，可在大流行期间使用。</blockquote>\"You cannot go hire people who know how to make the mRNA. Those people don't exist,\" he told investors.<blockquote>“你不能雇佣知道如何制造mRNA的人。这些人并不存在，”他告诉投资者。</blockquote>Pharma shares lost ground elsewhere too, with Germany's Curevac(5CV.DE), which has sought approval for its COVID-19 vaccine, tumbling as much as 15%.<blockquote>其他地方的制药股也下跌，德国Curevac(5CV.DE)股价下跌15%，该公司已寻求其COVID-19疫苗的批准。</blockquote>Chinese vaccine makersslumpedwith CanSino Biologics Inc , a single-dose COVID-19 vaccine maker, down 16%. Its Hong Kong shares(6185.HK)dived as much as 22%. Shares in London-listed AstraZeneca(AZN.L)were largely unchanged.<blockquote>中国疫苗制造商股价暴跌，单剂COVID-19疫苗制造商康希诺生物公司股价下跌16%。其港股（6185.HK）跌幅高达22%。在伦敦上市的阿斯利康(AZN.L)的股价基本没有变化。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Global pharma shares sink as Biden backs COVID-19 vaccine IP waiver<blockquote>拜登支持COVID-19疫苗知识产权豁免，全球制药股下跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGlobal pharma shares sink as Biden backs COVID-19 vaccine IP waiver<blockquote>拜登支持COVID-19疫苗知识产权豁免，全球制药股下跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nreuters2021-05-06 22:38\n\n</h4>\n</header>\n<article>\nShares of COVID-19 vaccine makers plungedafter U.S. President Joe Bidenbacked a proposed waiver for intellectual property rightseven as the pharmaceutical industry, analysts and experts doubted its impact, saying the real problem is a lack of raw materials and know-how.<blockquote>在美国总统乔·拜登支持拟议的知识产权豁免后，COVID-19疫苗制造商的股价暴跌尽管制药行业，分析师和专家仍怀疑其影响，称真正的问题是缺乏原材料和专业知识。</blockquote>Pfizer, Moderna, Novavax(NVAX.O)and U.S. shares of BioNTech were down between 4% and 10% on Thursday. The slide in stocks was understandable, but likely an over-reaction, Zhiqiang Shu, senior biotechnology analyst at Berenberg in New York, said.<blockquote>辉瑞、Moderna、Novavax(NVAX.O)和BioNTech的美股周四下跌4%至10%。纽约贝伦贝格高级生物技术分析师舒志强表示，股市下跌是可以理解的，但可能是反应过度。</blockquote>\"The production of mRNA vaccines is not just about intellectual property. A lot of other things are in play, such as manufacturing know-how and capacity. Other companies or countries are unlikely to produce mRNA shots quickly,\" he said.<blockquote>“mRNA疫苗的生产不仅仅与知识产权有关。还有很多其他因素在起作用，例如制造技术和产能。其他公司或国家不太可能快速生产mRNA疫苗，”他说。</blockquote>The Biden administration move drew applause from patent activists and the World Health Organization as it could increase availability of vaccines to poorer nations including India, which is under the grip of a deadly second wave of infection.<blockquote>拜登政府的举动赢得了专利活动人士和世界卫生组织的掌声，因为它可能会增加包括印度在内的较贫穷国家的疫苗供应，印度正受到致命的第二波感染。</blockquote>However, implementing such a move could be a lengthy process as all 164 WTO member countries are required to arrive at a consent.<blockquote>然而，实施这一举措可能是一个漫长的过程，因为所有164个世贸组织成员国都需要达成一致。</blockquote>The pharmaceutical industry, which has long defended patents as the key to research and development of new treatments, criticized the move, with its biggest lobby group warning that it would undermine pandemic response and compromise safety.<blockquote>长期以来一直捍卫专利是新疗法研发关键的制药业批评了此举，其最大的游说团体警告称，这将破坏大流行应对措施并损害安全。</blockquote>Several pharmaceutical analysts said IP waivers may on the surface help a world facing a pandemic, but manufacturing the vaccines was a barrier.<blockquote>几位制药分析师表示，知识产权豁免表面上可能有助于面临大流行的世界，但生产疫苗是一个障碍。</blockquote>Jefferies analyst Michael Yee said while the proposal was not a good \"headline\" for biotech and could affect earnings, in reality, the bottleneck is neither access nor patents (or price) but simply that there aren't enough vials, raw materials.<blockquote>杰富瑞(Jefferies)分析师Michael Yee表示，虽然该提案对生物技术来说不是一个好的“头条新闻”，并且可能会影响盈利，但实际上，瓶颈既不是获取也不是专利（或价格），而只是没有足够的小瓶和原材料。</blockquote>It would probably take a year after an IP deal was struck for anyone to make a vaccine, Scott Gottlieb, former head of the U.S. Food and Drug Administration and Pfizer board member said in a CNBC interview.<blockquote>美国前总统斯科特·戈特利布(Scott Gottlieb)表示，在达成知识产权协议后，任何人都可能需要一年时间才能制造疫苗。美国食品药品监督管理局和辉瑞董事会成员在接受CNBC采访时表示。</blockquote>Moderna CEO Stephan Bancel too doubted if the IP waiver would help as its technology has been open since October to anyone for use during the pandemic.<blockquote>Moderna首席执行官Stephan Bancel也怀疑知识产权豁免是否会有所帮助，因为其技术自10月份以来一直向任何人开放，可在大流行期间使用。</blockquote>\"You cannot go hire people who know how to make the mRNA. Those people don't exist,\" he told investors.<blockquote>“你不能雇佣知道如何制造mRNA的人。这些人并不存在，”他告诉投资者。</blockquote>Pharma shares lost ground elsewhere too, with Germany's Curevac(5CV.DE), which has sought approval for its COVID-19 vaccine, tumbling as much as 15%.<blockquote>其他地方的制药股也下跌，德国Curevac(5CV.DE)股价下跌15%，该公司已寻求其COVID-19疫苗的批准。</blockquote>Chinese vaccine makersslumpedwith CanSino Biologics Inc , a single-dose COVID-19 vaccine maker, down 16%. Its Hong Kong shares(6185.HK)dived as much as 22%. Shares in London-listed AstraZeneca(AZN.L)were largely unchanged.<blockquote>中国疫苗制造商股价暴跌，单剂COVID-19疫苗制造商康希诺生物公司股价下跌16%。其港股（6185.HK）跌幅高达22%。在伦敦上市的阿斯利康(AZN.L)的股价基本没有变化。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/pharma-shares-reel-after-biden-backs-covid-19-vaccine-ip-waiver-2021-05-06/\">reuters</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/pharma-shares-reel-after-biden-backs-covid-19-vaccine-ip-waiver-2021-05-06/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1139680950","content_text":"Shares of COVID-19 vaccine makers plungedafter U.S. President Joe Bidenbacked a proposed waiver for intellectual property rightseven as the pharmaceutical industry, analysts and experts doubted its impact, saying the real problem is a lack of raw materials and know-how.Pfizer, Moderna, Novavax(NVAX.O)and U.S. shares of BioNTech were down between 4% and 10% on Thursday. The slide in stocks was understandable, but likely an over-reaction, Zhiqiang Shu, senior biotechnology analyst at Berenberg in New York, said.\"The production of mRNA vaccines is not just about intellectual property. A lot of other things are in play, such as manufacturing know-how and capacity. Other companies or countries are unlikely to produce mRNA shots quickly,\" he said.The Biden administration move drew applause from patent activists and the World Health Organization as it could increase availability of vaccines to poorer nations including India, which is under the grip of a deadly second wave of infection.However, implementing such a move could be a lengthy process as all 164 WTO member countries are required to arrive at a consent.The pharmaceutical industry, which has long defended patents as the key to research and development of new treatments, criticized the move, with its biggest lobby group warning that it would undermine pandemic response and compromise safety.Several pharmaceutical analysts said IP waivers may on the surface help a world facing a pandemic, but manufacturing the vaccines was a barrier.Jefferies analyst Michael Yee said while the proposal was not a good \"headline\" for biotech and could affect earnings, in reality, the bottleneck is neither access nor patents (or price) but simply that there aren't enough vials, raw materials.It would probably take a year after an IP deal was struck for anyone to make a vaccine, Scott Gottlieb, former head of the U.S. Food and Drug Administration and Pfizer board member said in a CNBC interview.Moderna CEO Stephan Bancel too doubted if the IP waiver would help as its technology has been open since October to anyone for use during the pandemic.\"You cannot go hire people who know how to make the mRNA. Those people don't exist,\" he told investors.Pharma shares lost ground elsewhere too, with Germany's Curevac(5CV.DE), which has sought approval for its COVID-19 vaccine, tumbling as much as 15%.Chinese vaccine makersslumpedwith CanSino Biologics Inc , a single-dose COVID-19 vaccine maker, down 16%. Its Hong Kong shares(6185.HK)dived as much as 22%. Shares in London-listed AstraZeneca(AZN.L)were largely unchanged.","news_type":1,"symbols_score_info":{}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":104176349,"gmtCreate":1620368648381,"gmtModify":1634205710552,"author":{"id":"3574823733614024","authorId":"3574823733614024","name":"Bibop","avatar":"https://static.tigerbbs.com/5c9cf1e4cff885e3bf9913697004534b","vip":1,"crmLevel":11,"crmLevelSwitch":0,"idStr":"3574823733614024","authorIdStr":"3574823733614024"},"htmlText":"Greedy pharma company got slash.&nbsp;","listText":"Greedy pharma company got slash.&nbsp;","text":"Greedy pharma company got slash.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/104176349","repostId":1139680950,"repostType":4,"repost":{"id":"1139680950","kind":"news","pubTimestamp":1620311931,"share":"https://www.laohu8.com/m/news/1139680950?lang=zh_CN&edition=full","pubTime":"2021-05-06 22:38","market":"us","language":"en","title":"Global pharma shares sink as Biden backs COVID-19 vaccine IP waiver<blockquote>拜登支持COVID-19疫苗知识产权豁免，全球制药股下跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1139680950","media":"reuters","summary":"Shares of COVID-19 vaccine makers plungedafter U.S. President Joe Bidenbacked a proposed waiver for ","content":"Shares of COVID-19 vaccine makers plungedafter U.S. President Joe Bidenbacked a proposed waiver for intellectual property rightseven as the pharmaceutical industry, analysts and experts doubted its impact, saying the real problem is a lack of raw materials and know-how.<blockquote>在美国总统乔·拜登支持拟议的知识产权豁免后，COVID-19疫苗制造商的股价暴跌尽管制药行业，分析师和专家仍怀疑其影响，称真正的问题是缺乏原材料和专业知识。</blockquote>Pfizer, Moderna, Novavax(NVAX.O)and U.S. shares of BioNTech were down between 4% and 10% on Thursday. The slide in stocks was understandable, but likely an over-reaction, Zhiqiang Shu, senior biotechnology analyst at Berenberg in New York, said.<blockquote>辉瑞、Moderna、Novavax(NVAX.O)和BioNTech的美股周四下跌4%至10%。纽约贝伦贝格高级生物技术分析师舒志强表示，股市下跌是可以理解的，但可能是反应过度。</blockquote>\"The production of mRNA vaccines is not just about intellectual property. A lot of other things are in play, such as manufacturing know-how and capacity. Other companies or countries are unlikely to produce mRNA shots quickly,\" he said.<blockquote>“mRNA疫苗的生产不仅仅与知识产权有关。还有很多其他因素在起作用，例如制造技术和产能。其他公司或国家不太可能快速生产mRNA疫苗，”他说。</blockquote>The Biden administration move drew applause from patent activists and the World Health Organization as it could increase availability of vaccines to poorer nations including India, which is under the grip of a deadly second wave of infection.<blockquote>拜登政府的举动赢得了专利活动人士和世界卫生组织的掌声，因为它可能会增加包括印度在内的较贫穷国家的疫苗供应，印度正受到致命的第二波感染。</blockquote>However, implementing such a move could be a lengthy process as all 164 WTO member countries are required to arrive at a consent.<blockquote>然而，实施这一举措可能是一个漫长的过程，因为所有164个世贸组织成员国都需要达成一致。</blockquote>The pharmaceutical industry, which has long defended patents as the key to research and development of new treatments, criticized the move, with its biggest lobby group warning that it would undermine pandemic response and compromise safety.<blockquote>长期以来一直捍卫专利是新疗法研发关键的制药业批评了此举，其最大的游说团体警告称，这将破坏大流行应对措施并损害安全。</blockquote>Several pharmaceutical analysts said IP waivers may on the surface help a world facing a pandemic, but manufacturing the vaccines was a barrier.<blockquote>几位制药分析师表示，知识产权豁免表面上可能有助于面临大流行的世界，但生产疫苗是一个障碍。</blockquote>Jefferies analyst Michael Yee said while the proposal was not a good \"headline\" for biotech and could affect earnings, in reality, the bottleneck is neither access nor patents (or price) but simply that there aren't enough vials, raw materials.<blockquote>杰富瑞(Jefferies)分析师Michael Yee表示，虽然该提案对生物技术来说不是一个好的“头条新闻”，并且可能会影响盈利，但实际上，瓶颈既不是获取也不是专利（或价格），而只是没有足够的小瓶和原材料。</blockquote>It would probably take a year after an IP deal was struck for anyone to make a vaccine, Scott Gottlieb, former head of the U.S. Food and Drug Administration and Pfizer board member said in a CNBC interview.<blockquote>美国前总统斯科特·戈特利布(Scott Gottlieb)表示，在达成知识产权协议后，任何人都可能需要一年时间才能制造疫苗。美国食品药品监督管理局和辉瑞董事会成员在接受CNBC采访时表示。</blockquote>Moderna CEO Stephan Bancel too doubted if the IP waiver would help as its technology has been open since October to anyone for use during the pandemic.<blockquote>Moderna首席执行官Stephan Bancel也怀疑知识产权豁免是否会有所帮助，因为其技术自10月份以来一直向任何人开放，可在大流行期间使用。</blockquote>\"You cannot go hire people who know how to make the mRNA. Those people don't exist,\" he told investors.<blockquote>“你不能雇佣知道如何制造mRNA的人。这些人并不存在，”他告诉投资者。</blockquote>Pharma shares lost ground elsewhere too, with Germany's Curevac(5CV.DE), which has sought approval for its COVID-19 vaccine, tumbling as much as 15%.<blockquote>其他地方的制药股也下跌，德国Curevac(5CV.DE)股价下跌15%，该公司已寻求其COVID-19疫苗的批准。</blockquote>Chinese vaccine makersslumpedwith CanSino Biologics Inc , a single-dose COVID-19 vaccine maker, down 16%. Its Hong Kong shares(6185.HK)dived as much as 22%. Shares in London-listed AstraZeneca(AZN.L)were largely unchanged.<blockquote>中国疫苗制造商股价暴跌，单剂COVID-19疫苗制造商康希诺生物公司股价下跌16%。其港股（6185.HK）跌幅高达22%。在伦敦上市的阿斯利康(AZN.L)的股价基本没有变化。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Global pharma shares sink as Biden backs COVID-19 vaccine IP waiver<blockquote>拜登支持COVID-19疫苗知识产权豁免，全球制药股下跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGlobal pharma shares sink as Biden backs COVID-19 vaccine IP waiver<blockquote>拜登支持COVID-19疫苗知识产权豁免，全球制药股下跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nreuters2021-05-06 22:38\n\n</h4>\n</header>\n<article>\nShares of COVID-19 vaccine makers plungedafter U.S. President Joe Bidenbacked a proposed waiver for intellectual property rightseven as the pharmaceutical industry, analysts and experts doubted its impact, saying the real problem is a lack of raw materials and know-how.<blockquote>在美国总统乔·拜登支持拟议的知识产权豁免后，COVID-19疫苗制造商的股价暴跌尽管制药行业，分析师和专家仍怀疑其影响，称真正的问题是缺乏原材料和专业知识。</blockquote>Pfizer, Moderna, Novavax(NVAX.O)and U.S. shares of BioNTech were down between 4% and 10% on Thursday. The slide in stocks was understandable, but likely an over-reaction, Zhiqiang Shu, senior biotechnology analyst at Berenberg in New York, said.<blockquote>辉瑞、Moderna、Novavax(NVAX.O)和BioNTech的美股周四下跌4%至10%。纽约贝伦贝格高级生物技术分析师舒志强表示，股市下跌是可以理解的，但可能是反应过度。</blockquote>\"The production of mRNA vaccines is not just about intellectual property. A lot of other things are in play, such as manufacturing know-how and capacity. Other companies or countries are unlikely to produce mRNA shots quickly,\" he said.<blockquote>“mRNA疫苗的生产不仅仅与知识产权有关。还有很多其他因素在起作用，例如制造技术和产能。其他公司或国家不太可能快速生产mRNA疫苗，”他说。</blockquote>The Biden administration move drew applause from patent activists and the World Health Organization as it could increase availability of vaccines to poorer nations including India, which is under the grip of a deadly second wave of infection.<blockquote>拜登政府的举动赢得了专利活动人士和世界卫生组织的掌声，因为它可能会增加包括印度在内的较贫穷国家的疫苗供应，印度正受到致命的第二波感染。</blockquote>However, implementing such a move could be a lengthy process as all 164 WTO member countries are required to arrive at a consent.<blockquote>然而，实施这一举措可能是一个漫长的过程，因为所有164个世贸组织成员国都需要达成一致。</blockquote>The pharmaceutical industry, which has long defended patents as the key to research and development of new treatments, criticized the move, with its biggest lobby group warning that it would undermine pandemic response and compromise safety.<blockquote>长期以来一直捍卫专利是新疗法研发关键的制药业批评了此举，其最大的游说团体警告称，这将破坏大流行应对措施并损害安全。</blockquote>Several pharmaceutical analysts said IP waivers may on the surface help a world facing a pandemic, but manufacturing the vaccines was a barrier.<blockquote>几位制药分析师表示，知识产权豁免表面上可能有助于面临大流行的世界，但生产疫苗是一个障碍。</blockquote>Jefferies analyst Michael Yee said while the proposal was not a good \"headline\" for biotech and could affect earnings, in reality, the bottleneck is neither access nor patents (or price) but simply that there aren't enough vials, raw materials.<blockquote>杰富瑞(Jefferies)分析师Michael Yee表示，虽然该提案对生物技术来说不是一个好的“头条新闻”，并且可能会影响盈利，但实际上，瓶颈既不是获取也不是专利（或价格），而只是没有足够的小瓶和原材料。</blockquote>It would probably take a year after an IP deal was struck for anyone to make a vaccine, Scott Gottlieb, former head of the U.S. Food and Drug Administration and Pfizer board member said in a CNBC interview.<blockquote>美国前总统斯科特·戈特利布(Scott Gottlieb)表示，在达成知识产权协议后，任何人都可能需要一年时间才能制造疫苗。美国食品药品监督管理局和辉瑞董事会成员在接受CNBC采访时表示。</blockquote>Moderna CEO Stephan Bancel too doubted if the IP waiver would help as its technology has been open since October to anyone for use during the pandemic.<blockquote>Moderna首席执行官Stephan Bancel也怀疑知识产权豁免是否会有所帮助，因为其技术自10月份以来一直向任何人开放，可在大流行期间使用。</blockquote>\"You cannot go hire people who know how to make the mRNA. Those people don't exist,\" he told investors.<blockquote>“你不能雇佣知道如何制造mRNA的人。这些人并不存在，”他告诉投资者。</blockquote>Pharma shares lost ground elsewhere too, with Germany's Curevac(5CV.DE), which has sought approval for its COVID-19 vaccine, tumbling as much as 15%.<blockquote>其他地方的制药股也下跌，德国Curevac(5CV.DE)股价下跌15%，该公司已寻求其COVID-19疫苗的批准。</blockquote>Chinese vaccine makersslumpedwith CanSino Biologics Inc , a single-dose COVID-19 vaccine maker, down 16%. Its Hong Kong shares(6185.HK)dived as much as 22%. Shares in London-listed AstraZeneca(AZN.L)were largely unchanged.<blockquote>中国疫苗制造商股价暴跌，单剂COVID-19疫苗制造商康希诺生物公司股价下跌16%。其港股（6185.HK）跌幅高达22%。在伦敦上市的阿斯利康(AZN.L)的股价基本没有变化。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/pharma-shares-reel-after-biden-backs-covid-19-vaccine-ip-waiver-2021-05-06/\">reuters</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/pharma-shares-reel-after-biden-backs-covid-19-vaccine-ip-waiver-2021-05-06/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1139680950","content_text":"Shares of COVID-19 vaccine makers plungedafter U.S. President Joe Bidenbacked a proposed waiver for intellectual property rightseven as the pharmaceutical industry, analysts and experts doubted its impact, saying the real problem is a lack of raw materials and know-how.Pfizer, Moderna, Novavax(NVAX.O)and U.S. shares of BioNTech were down between 4% and 10% on Thursday. The slide in stocks was understandable, but likely an over-reaction, Zhiqiang Shu, senior biotechnology analyst at Berenberg in New York, said.\"The production of mRNA vaccines is not just about intellectual property. A lot of other things are in play, such as manufacturing know-how and capacity. Other companies or countries are unlikely to produce mRNA shots quickly,\" he said.The Biden administration move drew applause from patent activists and the World Health Organization as it could increase availability of vaccines to poorer nations including India, which is under the grip of a deadly second wave of infection.However, implementing such a move could be a lengthy process as all 164 WTO member countries are required to arrive at a consent.The pharmaceutical industry, which has long defended patents as the key to research and development of new treatments, criticized the move, with its biggest lobby group warning that it would undermine pandemic response and compromise safety.Several pharmaceutical analysts said IP waivers may on the surface help a world facing a pandemic, but manufacturing the vaccines was a barrier.Jefferies analyst Michael Yee said while the proposal was not a good \"headline\" for biotech and could affect earnings, in reality, the bottleneck is neither access nor patents (or price) but simply that there aren't enough vials, raw materials.It would probably take a year after an IP deal was struck for anyone to make a vaccine, Scott Gottlieb, former head of the U.S. Food and Drug Administration and Pfizer board member said in a CNBC interview.Moderna CEO Stephan Bancel too doubted if the IP waiver would help as its technology has been open since October to anyone for use during the pandemic.\"You cannot go hire people who know how to make the mRNA. Those people don't exist,\" he told investors.Pharma shares lost ground elsewhere too, with Germany's Curevac(5CV.DE), which has sought approval for its COVID-19 vaccine, tumbling as much as 15%.Chinese vaccine makersslumpedwith CanSino Biologics Inc , a single-dose COVID-19 vaccine maker, down 16%. Its Hong Kong shares(6185.HK)dived as much as 22%. Shares in London-listed AstraZeneca(AZN.L)were largely unchanged.","news_type":1,"symbols_score_info":{}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":104153512,"gmtCreate":1620366523236,"gmtModify":1634205723549,"author":{"id":"3569805243820041","authorId":"3569805243820041","name":"mcwood","avatar":"https://static.tigerbbs.com/899c12565f32e74966bd8f5ceac09f7c","vip":1,"crmLevel":11,"crmLevelSwitch":0,"idStr":"3569805243820041","authorIdStr":"3569805243820041"},"htmlText":"[得意]&nbsp;","listText":"[得意]&nbsp;","text":"[得意]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/104153512","repostId":1139680950,"repostType":4,"repost":{"id":"1139680950","kind":"news","pubTimestamp":1620311931,"share":"https://www.laohu8.com/m/news/1139680950?lang=zh_CN&edition=full","pubTime":"2021-05-06 22:38","market":"us","language":"en","title":"Global pharma shares sink as Biden backs COVID-19 vaccine IP waiver<blockquote>拜登支持COVID-19疫苗知识产权豁免，全球制药股下跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1139680950","media":"reuters","summary":"Shares of COVID-19 vaccine makers plungedafter U.S. President Joe Bidenbacked a proposed waiver for ","content":"Shares of COVID-19 vaccine makers plungedafter U.S. President Joe Bidenbacked a proposed waiver for intellectual property rightseven as the pharmaceutical industry, analysts and experts doubted its impact, saying the real problem is a lack of raw materials and know-how.<blockquote>在美国总统乔·拜登支持拟议的知识产权豁免后，COVID-19疫苗制造商的股价暴跌尽管制药行业，分析师和专家仍怀疑其影响，称真正的问题是缺乏原材料和专业知识。</blockquote>Pfizer, Moderna, Novavax(NVAX.O)and U.S. shares of BioNTech were down between 4% and 10% on Thursday. The slide in stocks was understandable, but likely an over-reaction, Zhiqiang Shu, senior biotechnology analyst at Berenberg in New York, said.<blockquote>辉瑞、Moderna、Novavax(NVAX.O)和BioNTech的美股周四下跌4%至10%。纽约贝伦贝格高级生物技术分析师舒志强表示，股市下跌是可以理解的，但可能是反应过度。</blockquote>\"The production of mRNA vaccines is not just about intellectual property. A lot of other things are in play, such as manufacturing know-how and capacity. Other companies or countries are unlikely to produce mRNA shots quickly,\" he said.<blockquote>“mRNA疫苗的生产不仅仅与知识产权有关。还有很多其他因素在起作用，例如制造技术和产能。其他公司或国家不太可能快速生产mRNA疫苗，”他说。</blockquote>The Biden administration move drew applause from patent activists and the World Health Organization as it could increase availability of vaccines to poorer nations including India, which is under the grip of a deadly second wave of infection.<blockquote>拜登政府的举动赢得了专利活动人士和世界卫生组织的掌声，因为它可能会增加包括印度在内的较贫穷国家的疫苗供应，印度正受到致命的第二波感染。</blockquote>However, implementing such a move could be a lengthy process as all 164 WTO member countries are required to arrive at a consent.<blockquote>然而，实施这一举措可能是一个漫长的过程，因为所有164个世贸组织成员国都需要达成一致。</blockquote>The pharmaceutical industry, which has long defended patents as the key to research and development of new treatments, criticized the move, with its biggest lobby group warning that it would undermine pandemic response and compromise safety.<blockquote>长期以来一直捍卫专利是新疗法研发关键的制药业批评了此举，其最大的游说团体警告称，这将破坏大流行应对措施并损害安全。</blockquote>Several pharmaceutical analysts said IP waivers may on the surface help a world facing a pandemic, but manufacturing the vaccines was a barrier.<blockquote>几位制药分析师表示，知识产权豁免表面上可能有助于面临大流行的世界，但生产疫苗是一个障碍。</blockquote>Jefferies analyst Michael Yee said while the proposal was not a good \"headline\" for biotech and could affect earnings, in reality, the bottleneck is neither access nor patents (or price) but simply that there aren't enough vials, raw materials.<blockquote>杰富瑞(Jefferies)分析师Michael Yee表示，虽然该提案对生物技术来说不是一个好的“头条新闻”，并且可能会影响盈利，但实际上，瓶颈既不是获取也不是专利（或价格），而只是没有足够的小瓶和原材料。</blockquote>It would probably take a year after an IP deal was struck for anyone to make a vaccine, Scott Gottlieb, former head of the U.S. Food and Drug Administration and Pfizer board member said in a CNBC interview.<blockquote>美国前总统斯科特·戈特利布(Scott Gottlieb)表示，在达成知识产权协议后，任何人都可能需要一年时间才能制造疫苗。美国食品药品监督管理局和辉瑞董事会成员在接受CNBC采访时表示。</blockquote>Moderna CEO Stephan Bancel too doubted if the IP waiver would help as its technology has been open since October to anyone for use during the pandemic.<blockquote>Moderna首席执行官Stephan Bancel也怀疑知识产权豁免是否会有所帮助，因为其技术自10月份以来一直向任何人开放，可在大流行期间使用。</blockquote>\"You cannot go hire people who know how to make the mRNA. Those people don't exist,\" he told investors.<blockquote>“你不能雇佣知道如何制造mRNA的人。这些人并不存在，”他告诉投资者。</blockquote>Pharma shares lost ground elsewhere too, with Germany's Curevac(5CV.DE), which has sought approval for its COVID-19 vaccine, tumbling as much as 15%.<blockquote>其他地方的制药股也下跌，德国Curevac(5CV.DE)股价下跌15%，该公司已寻求其COVID-19疫苗的批准。</blockquote>Chinese vaccine makersslumpedwith CanSino Biologics Inc , a single-dose COVID-19 vaccine maker, down 16%. Its Hong Kong shares(6185.HK)dived as much as 22%. Shares in London-listed AstraZeneca(AZN.L)were largely unchanged.<blockquote>中国疫苗制造商股价暴跌，单剂COVID-19疫苗制造商康希诺生物公司股价下跌16%。其港股（6185.HK）跌幅高达22%。在伦敦上市的阿斯利康(AZN.L)的股价基本没有变化。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Global pharma shares sink as Biden backs COVID-19 vaccine IP waiver<blockquote>拜登支持COVID-19疫苗知识产权豁免，全球制药股下跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGlobal pharma shares sink as Biden backs COVID-19 vaccine IP waiver<blockquote>拜登支持COVID-19疫苗知识产权豁免，全球制药股下跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nreuters2021-05-06 22:38\n\n</h4>\n</header>\n<article>\nShares of COVID-19 vaccine makers plungedafter U.S. President Joe Bidenbacked a proposed waiver for intellectual property rightseven as the pharmaceutical industry, analysts and experts doubted its impact, saying the real problem is a lack of raw materials and know-how.<blockquote>在美国总统乔·拜登支持拟议的知识产权豁免后，COVID-19疫苗制造商的股价暴跌尽管制药行业，分析师和专家仍怀疑其影响，称真正的问题是缺乏原材料和专业知识。</blockquote>Pfizer, Moderna, Novavax(NVAX.O)and U.S. shares of BioNTech were down between 4% and 10% on Thursday. The slide in stocks was understandable, but likely an over-reaction, Zhiqiang Shu, senior biotechnology analyst at Berenberg in New York, said.<blockquote>辉瑞、Moderna、Novavax(NVAX.O)和BioNTech的美股周四下跌4%至10%。纽约贝伦贝格高级生物技术分析师舒志强表示，股市下跌是可以理解的，但可能是反应过度。</blockquote>\"The production of mRNA vaccines is not just about intellectual property. A lot of other things are in play, such as manufacturing know-how and capacity. Other companies or countries are unlikely to produce mRNA shots quickly,\" he said.<blockquote>“mRNA疫苗的生产不仅仅与知识产权有关。还有很多其他因素在起作用，例如制造技术和产能。其他公司或国家不太可能快速生产mRNA疫苗，”他说。</blockquote>The Biden administration move drew applause from patent activists and the World Health Organization as it could increase availability of vaccines to poorer nations including India, which is under the grip of a deadly second wave of infection.<blockquote>拜登政府的举动赢得了专利活动人士和世界卫生组织的掌声，因为它可能会增加包括印度在内的较贫穷国家的疫苗供应，印度正受到致命的第二波感染。</blockquote>However, implementing such a move could be a lengthy process as all 164 WTO member countries are required to arrive at a consent.<blockquote>然而，实施这一举措可能是一个漫长的过程，因为所有164个世贸组织成员国都需要达成一致。</blockquote>The pharmaceutical industry, which has long defended patents as the key to research and development of new treatments, criticized the move, with its biggest lobby group warning that it would undermine pandemic response and compromise safety.<blockquote>长期以来一直捍卫专利是新疗法研发关键的制药业批评了此举，其最大的游说团体警告称，这将破坏大流行应对措施并损害安全。</blockquote>Several pharmaceutical analysts said IP waivers may on the surface help a world facing a pandemic, but manufacturing the vaccines was a barrier.<blockquote>几位制药分析师表示，知识产权豁免表面上可能有助于面临大流行的世界，但生产疫苗是一个障碍。</blockquote>Jefferies analyst Michael Yee said while the proposal was not a good \"headline\" for biotech and could affect earnings, in reality, the bottleneck is neither access nor patents (or price) but simply that there aren't enough vials, raw materials.<blockquote>杰富瑞(Jefferies)分析师Michael Yee表示，虽然该提案对生物技术来说不是一个好的“头条新闻”，并且可能会影响盈利，但实际上，瓶颈既不是获取也不是专利（或价格），而只是没有足够的小瓶和原材料。</blockquote>It would probably take a year after an IP deal was struck for anyone to make a vaccine, Scott Gottlieb, former head of the U.S. Food and Drug Administration and Pfizer board member said in a CNBC interview.<blockquote>美国前总统斯科特·戈特利布(Scott Gottlieb)表示，在达成知识产权协议后，任何人都可能需要一年时间才能制造疫苗。美国食品药品监督管理局和辉瑞董事会成员在接受CNBC采访时表示。</blockquote>Moderna CEO Stephan Bancel too doubted if the IP waiver would help as its technology has been open since October to anyone for use during the pandemic.<blockquote>Moderna首席执行官Stephan Bancel也怀疑知识产权豁免是否会有所帮助，因为其技术自10月份以来一直向任何人开放，可在大流行期间使用。</blockquote>\"You cannot go hire people who know how to make the mRNA. Those people don't exist,\" he told investors.<blockquote>“你不能雇佣知道如何制造mRNA的人。这些人并不存在，”他告诉投资者。</blockquote>Pharma shares lost ground elsewhere too, with Germany's Curevac(5CV.DE), which has sought approval for its COVID-19 vaccine, tumbling as much as 15%.<blockquote>其他地方的制药股也下跌，德国Curevac(5CV.DE)股价下跌15%，该公司已寻求其COVID-19疫苗的批准。</blockquote>Chinese vaccine makersslumpedwith CanSino Biologics Inc , a single-dose COVID-19 vaccine maker, down 16%. Its Hong Kong shares(6185.HK)dived as much as 22%. Shares in London-listed AstraZeneca(AZN.L)were largely unchanged.<blockquote>中国疫苗制造商股价暴跌，单剂COVID-19疫苗制造商康希诺生物公司股价下跌16%。其港股（6185.HK）跌幅高达22%。在伦敦上市的阿斯利康(AZN.L)的股价基本没有变化。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/pharma-shares-reel-after-biden-backs-covid-19-vaccine-ip-waiver-2021-05-06/\">reuters</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/pharma-shares-reel-after-biden-backs-covid-19-vaccine-ip-waiver-2021-05-06/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1139680950","content_text":"Shares of COVID-19 vaccine makers plungedafter U.S. President Joe Bidenbacked a proposed waiver for intellectual property rightseven as the pharmaceutical industry, analysts and experts doubted its impact, saying the real problem is a lack of raw materials and know-how.Pfizer, Moderna, Novavax(NVAX.O)and U.S. shares of BioNTech were down between 4% and 10% on Thursday. The slide in stocks was understandable, but likely an over-reaction, Zhiqiang Shu, senior biotechnology analyst at Berenberg in New York, said.\"The production of mRNA vaccines is not just about intellectual property. A lot of other things are in play, such as manufacturing know-how and capacity. Other companies or countries are unlikely to produce mRNA shots quickly,\" he said.The Biden administration move drew applause from patent activists and the World Health Organization as it could increase availability of vaccines to poorer nations including India, which is under the grip of a deadly second wave of infection.However, implementing such a move could be a lengthy process as all 164 WTO member countries are required to arrive at a consent.The pharmaceutical industry, which has long defended patents as the key to research and development of new treatments, criticized the move, with its biggest lobby group warning that it would undermine pandemic response and compromise safety.Several pharmaceutical analysts said IP waivers may on the surface help a world facing a pandemic, but manufacturing the vaccines was a barrier.Jefferies analyst Michael Yee said while the proposal was not a good \"headline\" for biotech and could affect earnings, in reality, the bottleneck is neither access nor patents (or price) but simply that there aren't enough vials, raw materials.It would probably take a year after an IP deal was struck for anyone to make a vaccine, Scott Gottlieb, former head of the U.S. Food and Drug Administration and Pfizer board member said in a CNBC interview.Moderna CEO Stephan Bancel too doubted if the IP waiver would help as its technology has been open since October to anyone for use during the pandemic.\"You cannot go hire people who know how to make the mRNA. Those people don't exist,\" he told investors.Pharma shares lost ground elsewhere too, with Germany's Curevac(5CV.DE), which has sought approval for its COVID-19 vaccine, tumbling as much as 15%.Chinese vaccine makersslumpedwith CanSino Biologics Inc , a single-dose COVID-19 vaccine maker, down 16%. Its Hong Kong shares(6185.HK)dived as much as 22%. Shares in London-listed AstraZeneca(AZN.L)were largely unchanged.","news_type":1,"symbols_score_info":{}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":104956747,"gmtCreate":1620351578789,"gmtModify":1634205854229,"author":{"id":"3569026924402821","authorId":"3569026924402821","name":"小股神来也","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":11,"crmLevelSwitch":0,"idStr":"3569026924402821","authorIdStr":"3569026924402821"},"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/104956747","repostId":1139680950,"repostType":4,"repost":{"id":"1139680950","kind":"news","pubTimestamp":1620311931,"share":"https://www.laohu8.com/m/news/1139680950?lang=zh_CN&edition=full","pubTime":"2021-05-06 22:38","market":"us","language":"en","title":"Global pharma shares sink as Biden backs COVID-19 vaccine IP waiver<blockquote>拜登支持COVID-19疫苗知识产权豁免，全球制药股下跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1139680950","media":"reuters","summary":"Shares of COVID-19 vaccine makers plungedafter U.S. President Joe Bidenbacked a proposed waiver for ","content":"Shares of COVID-19 vaccine makers plungedafter U.S. President Joe Bidenbacked a proposed waiver for intellectual property rightseven as the pharmaceutical industry, analysts and experts doubted its impact, saying the real problem is a lack of raw materials and know-how.<blockquote>在美国总统乔·拜登支持拟议的知识产权豁免后，COVID-19疫苗制造商的股价暴跌尽管制药行业，分析师和专家仍怀疑其影响，称真正的问题是缺乏原材料和专业知识。</blockquote>Pfizer, Moderna, Novavax(NVAX.O)and U.S. shares of BioNTech were down between 4% and 10% on Thursday. The slide in stocks was understandable, but likely an over-reaction, Zhiqiang Shu, senior biotechnology analyst at Berenberg in New York, said.<blockquote>辉瑞、Moderna、Novavax(NVAX.O)和BioNTech的美股周四下跌4%至10%。纽约贝伦贝格高级生物技术分析师舒志强表示，股市下跌是可以理解的，但可能是反应过度。</blockquote>\"The production of mRNA vaccines is not just about intellectual property. A lot of other things are in play, such as manufacturing know-how and capacity. Other companies or countries are unlikely to produce mRNA shots quickly,\" he said.<blockquote>“mRNA疫苗的生产不仅仅与知识产权有关。还有很多其他因素在起作用，例如制造技术和产能。其他公司或国家不太可能快速生产mRNA疫苗，”他说。</blockquote>The Biden administration move drew applause from patent activists and the World Health Organization as it could increase availability of vaccines to poorer nations including India, which is under the grip of a deadly second wave of infection.<blockquote>拜登政府的举动赢得了专利活动人士和世界卫生组织的掌声，因为它可能会增加包括印度在内的较贫穷国家的疫苗供应，印度正受到致命的第二波感染。</blockquote>However, implementing such a move could be a lengthy process as all 164 WTO member countries are required to arrive at a consent.<blockquote>然而，实施这一举措可能是一个漫长的过程，因为所有164个世贸组织成员国都需要达成一致。</blockquote>The pharmaceutical industry, which has long defended patents as the key to research and development of new treatments, criticized the move, with its biggest lobby group warning that it would undermine pandemic response and compromise safety.<blockquote>长期以来一直捍卫专利是新疗法研发关键的制药业批评了此举，其最大的游说团体警告称，这将破坏大流行应对措施并损害安全。</blockquote>Several pharmaceutical analysts said IP waivers may on the surface help a world facing a pandemic, but manufacturing the vaccines was a barrier.<blockquote>几位制药分析师表示，知识产权豁免表面上可能有助于面临大流行的世界，但生产疫苗是一个障碍。</blockquote>Jefferies analyst Michael Yee said while the proposal was not a good \"headline\" for biotech and could affect earnings, in reality, the bottleneck is neither access nor patents (or price) but simply that there aren't enough vials, raw materials.<blockquote>杰富瑞(Jefferies)分析师Michael Yee表示，虽然该提案对生物技术来说不是一个好的“头条新闻”，并且可能会影响盈利，但实际上，瓶颈既不是获取也不是专利（或价格），而只是没有足够的小瓶和原材料。</blockquote>It would probably take a year after an IP deal was struck for anyone to make a vaccine, Scott Gottlieb, former head of the U.S. Food and Drug Administration and Pfizer board member said in a CNBC interview.<blockquote>美国前总统斯科特·戈特利布(Scott Gottlieb)表示，在达成知识产权协议后，任何人都可能需要一年时间才能制造疫苗。美国食品药品监督管理局和辉瑞董事会成员在接受CNBC采访时表示。</blockquote>Moderna CEO Stephan Bancel too doubted if the IP waiver would help as its technology has been open since October to anyone for use during the pandemic.<blockquote>Moderna首席执行官Stephan Bancel也怀疑知识产权豁免是否会有所帮助，因为其技术自10月份以来一直向任何人开放，可在大流行期间使用。</blockquote>\"You cannot go hire people who know how to make the mRNA. Those people don't exist,\" he told investors.<blockquote>“你不能雇佣知道如何制造mRNA的人。这些人并不存在，”他告诉投资者。</blockquote>Pharma shares lost ground elsewhere too, with Germany's Curevac(5CV.DE), which has sought approval for its COVID-19 vaccine, tumbling as much as 15%.<blockquote>其他地方的制药股也下跌，德国Curevac(5CV.DE)股价下跌15%，该公司已寻求其COVID-19疫苗的批准。</blockquote>Chinese vaccine makersslumpedwith CanSino Biologics Inc , a single-dose COVID-19 vaccine maker, down 16%. Its Hong Kong shares(6185.HK)dived as much as 22%. Shares in London-listed AstraZeneca(AZN.L)were largely unchanged.<blockquote>中国疫苗制造商股价暴跌，单剂COVID-19疫苗制造商康希诺生物公司股价下跌16%。其港股（6185.HK）跌幅高达22%。在伦敦上市的阿斯利康(AZN.L)的股价基本没有变化。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Global pharma shares sink as Biden backs COVID-19 vaccine IP waiver<blockquote>拜登支持COVID-19疫苗知识产权豁免，全球制药股下跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGlobal pharma shares sink as Biden backs COVID-19 vaccine IP waiver<blockquote>拜登支持COVID-19疫苗知识产权豁免，全球制药股下跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nreuters2021-05-06 22:38\n\n</h4>\n</header>\n<article>\nShares of COVID-19 vaccine makers plungedafter U.S. President Joe Bidenbacked a proposed waiver for intellectual property rightseven as the pharmaceutical industry, analysts and experts doubted its impact, saying the real problem is a lack of raw materials and know-how.<blockquote>在美国总统乔·拜登支持拟议的知识产权豁免后，COVID-19疫苗制造商的股价暴跌尽管制药行业，分析师和专家仍怀疑其影响，称真正的问题是缺乏原材料和专业知识。</blockquote>Pfizer, Moderna, Novavax(NVAX.O)and U.S. shares of BioNTech were down between 4% and 10% on Thursday. The slide in stocks was understandable, but likely an over-reaction, Zhiqiang Shu, senior biotechnology analyst at Berenberg in New York, said.<blockquote>辉瑞、Moderna、Novavax(NVAX.O)和BioNTech的美股周四下跌4%至10%。纽约贝伦贝格高级生物技术分析师舒志强表示，股市下跌是可以理解的，但可能是反应过度。</blockquote>\"The production of mRNA vaccines is not just about intellectual property. A lot of other things are in play, such as manufacturing know-how and capacity. Other companies or countries are unlikely to produce mRNA shots quickly,\" he said.<blockquote>“mRNA疫苗的生产不仅仅与知识产权有关。还有很多其他因素在起作用，例如制造技术和产能。其他公司或国家不太可能快速生产mRNA疫苗，”他说。</blockquote>The Biden administration move drew applause from patent activists and the World Health Organization as it could increase availability of vaccines to poorer nations including India, which is under the grip of a deadly second wave of infection.<blockquote>拜登政府的举动赢得了专利活动人士和世界卫生组织的掌声，因为它可能会增加包括印度在内的较贫穷国家的疫苗供应，印度正受到致命的第二波感染。</blockquote>However, implementing such a move could be a lengthy process as all 164 WTO member countries are required to arrive at a consent.<blockquote>然而，实施这一举措可能是一个漫长的过程，因为所有164个世贸组织成员国都需要达成一致。</blockquote>The pharmaceutical industry, which has long defended patents as the key to research and development of new treatments, criticized the move, with its biggest lobby group warning that it would undermine pandemic response and compromise safety.<blockquote>长期以来一直捍卫专利是新疗法研发关键的制药业批评了此举，其最大的游说团体警告称，这将破坏大流行应对措施并损害安全。</blockquote>Several pharmaceutical analysts said IP waivers may on the surface help a world facing a pandemic, but manufacturing the vaccines was a barrier.<blockquote>几位制药分析师表示，知识产权豁免表面上可能有助于面临大流行的世界，但生产疫苗是一个障碍。</blockquote>Jefferies analyst Michael Yee said while the proposal was not a good \"headline\" for biotech and could affect earnings, in reality, the bottleneck is neither access nor patents (or price) but simply that there aren't enough vials, raw materials.<blockquote>杰富瑞(Jefferies)分析师Michael Yee表示，虽然该提案对生物技术来说不是一个好的“头条新闻”，并且可能会影响盈利，但实际上，瓶颈既不是获取也不是专利（或价格），而只是没有足够的小瓶和原材料。</blockquote>It would probably take a year after an IP deal was struck for anyone to make a vaccine, Scott Gottlieb, former head of the U.S. Food and Drug Administration and Pfizer board member said in a CNBC interview.<blockquote>美国前总统斯科特·戈特利布(Scott Gottlieb)表示，在达成知识产权协议后，任何人都可能需要一年时间才能制造疫苗。美国食品药品监督管理局和辉瑞董事会成员在接受CNBC采访时表示。</blockquote>Moderna CEO Stephan Bancel too doubted if the IP waiver would help as its technology has been open since October to anyone for use during the pandemic.<blockquote>Moderna首席执行官Stephan Bancel也怀疑知识产权豁免是否会有所帮助，因为其技术自10月份以来一直向任何人开放，可在大流行期间使用。</blockquote>\"You cannot go hire people who know how to make the mRNA. Those people don't exist,\" he told investors.<blockquote>“你不能雇佣知道如何制造mRNA的人。这些人并不存在，”他告诉投资者。</blockquote>Pharma shares lost ground elsewhere too, with Germany's Curevac(5CV.DE), which has sought approval for its COVID-19 vaccine, tumbling as much as 15%.<blockquote>其他地方的制药股也下跌，德国Curevac(5CV.DE)股价下跌15%，该公司已寻求其COVID-19疫苗的批准。</blockquote>Chinese vaccine makersslumpedwith CanSino Biologics Inc , a single-dose COVID-19 vaccine maker, down 16%. Its Hong Kong shares(6185.HK)dived as much as 22%. Shares in London-listed AstraZeneca(AZN.L)were largely unchanged.<blockquote>中国疫苗制造商股价暴跌，单剂COVID-19疫苗制造商康希诺生物公司股价下跌16%。其港股（6185.HK）跌幅高达22%。在伦敦上市的阿斯利康(AZN.L)的股价基本没有变化。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/pharma-shares-reel-after-biden-backs-covid-19-vaccine-ip-waiver-2021-05-06/\">reuters</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/pharma-shares-reel-after-biden-backs-covid-19-vaccine-ip-waiver-2021-05-06/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1139680950","content_text":"Shares of COVID-19 vaccine makers plungedafter U.S. President Joe Bidenbacked a proposed waiver for intellectual property rightseven as the pharmaceutical industry, analysts and experts doubted its impact, saying the real problem is a lack of raw materials and know-how.Pfizer, Moderna, Novavax(NVAX.O)and U.S. shares of BioNTech were down between 4% and 10% on Thursday. The slide in stocks was understandable, but likely an over-reaction, Zhiqiang Shu, senior biotechnology analyst at Berenberg in New York, said.\"The production of mRNA vaccines is not just about intellectual property. A lot of other things are in play, such as manufacturing know-how and capacity. Other companies or countries are unlikely to produce mRNA shots quickly,\" he said.The Biden administration move drew applause from patent activists and the World Health Organization as it could increase availability of vaccines to poorer nations including India, which is under the grip of a deadly second wave of infection.However, implementing such a move could be a lengthy process as all 164 WTO member countries are required to arrive at a consent.The pharmaceutical industry, which has long defended patents as the key to research and development of new treatments, criticized the move, with its biggest lobby group warning that it would undermine pandemic response and compromise safety.Several pharmaceutical analysts said IP waivers may on the surface help a world facing a pandemic, but manufacturing the vaccines was a barrier.Jefferies analyst Michael Yee said while the proposal was not a good \"headline\" for biotech and could affect earnings, in reality, the bottleneck is neither access nor patents (or price) but simply that there aren't enough vials, raw materials.It would probably take a year after an IP deal was struck for anyone to make a vaccine, Scott Gottlieb, former head of the U.S. Food and Drug Administration and Pfizer board member said in a CNBC interview.Moderna CEO Stephan Bancel too doubted if the IP waiver would help as its technology has been open since October to anyone for use during the pandemic.\"You cannot go hire people who know how to make the mRNA. Those people don't exist,\" he told investors.Pharma shares lost ground elsewhere too, with Germany's Curevac(5CV.DE), which has sought approval for its COVID-19 vaccine, tumbling as much as 15%.Chinese vaccine makersslumpedwith CanSino Biologics Inc , a single-dose COVID-19 vaccine maker, down 16%. Its Hong Kong shares(6185.HK)dived as much as 22%. Shares in London-listed AstraZeneca(AZN.L)were largely unchanged.","news_type":1,"symbols_score_info":{}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4250444,"gmtCreate":1620364223002,"gmtModify":1635501314469,"authorId":3555098609392330,"author":{"id":3555098609392330,"idStr":"3555098609392330","authorId":3555098609392330,"name":"茁壮成长的韭菜儿","avatar":"https://static.tigerbbs.com/63c1303fedfcd4cb51019f482b816ad5","vip":1,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":104956747,"type":1,"supId":0,"prevId":0,"content":"ok","text":"ok","html":"ok"},{"id":4250458,"gmtCreate":1620364281597,"gmtModify":1635501313601,"authorId":3569026924402821,"author":{"id":3569026924402821,"idStr":"3569026924402821","authorId":3569026924402821,"name":"小股神来也","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":104956747,"type":1,"supId":4250444,"prevId":0,"content":"oo","text":"oo","html":"oo"},{"id":4261965,"gmtCreate":1620457909881,"gmtModify":1635500430982,"authorId":3555098609392330,"author":{"id":3555098609392330,"idStr":"3555098609392330","authorId":3555098609392330,"name":"茁壮成长的韭菜儿","avatar":"https://static.tigerbbs.com/63c1303fedfcd4cb51019f482b816ad5","vip":1,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":104956747,"type":1,"supId":0,"prevId":0,"content":"ooo","text":"ooo","html":"ooo"}],"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":97,"commentSize":25,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1139680950","isCrawlerRequest":true}